The Clinical Core will recruit, diagnose and follow control subjects and patients with Alzheimer's disease (AD) and other dementias. We will provide well-subjects, clinical data and body fluids to investigators at UT Southwestern and other institutions. Our emphases will be (a) recruiting, evaluating and following controls and AD patients, (b) providing to investigators materials for antemortem and postmortem studies, (c) employing SPECT in the differential diagnosis of dementia, (d) increasing service to and data collection from minorities and other under served populations, (e) designing and participating in studies through the Alzheimer's Disease Study Unit (ADSU) and contributing data to the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (f) educating healthcare professionals in the diagnosis and management of dementing illness, and (g) analyzing and correlating our clinical data with neuropsychological, imaging, CSF and neuropathological findings. We will continue to train and to monitor staff at our North Texas and Northern Oklahoma Satellites, which have given us access to a significant number of African-Americans, Hispanics and Native Americans. We will also encode data and collect CSF for those sites. We will direct vigorous efforts to increasing our recruitment of controls and following patients whom we have evaluated. To maximize patient retention, we will undertake a user satisfaction survey with the Education and Information Transfer (EIT) Core. Our research efforts will be focused, with the help of the Statistics and Data Management (SDM) Core, on analysis of data we gather routinely in patient evaluations, such as assessments of mood and agitation. We will add to our database the CERAD Behavioral Rating Scale for Dementia, and will continue to refine our databasing operation with the help of the SDM Core. We will continue our clinicopathologic conferences cosponsored by the Neuropathology Core.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG012300-06
Application #
6295629
Study Section
Project Start
1999-04-01
Project End
2000-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
6
Fiscal Year
1999
Total Cost
Indirect Cost
City
Dallas
State
TX
Country
United States
Zip Code
75390
Ding, Kan; Tarumi, Takashi; Zhu, David C et al. (2018) Cardiorespiratory Fitness and White Matter Neuronal Fiber Integrity in Mild Cognitive Impairment. J Alzheimers Dis 61:729-739
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
LoBue, Christian; Woon, Fu L; Rossetti, Heidi C et al. (2018) Traumatic brain injury history and progression from mild cognitive impairment to Alzheimer disease. Neuropsychology 32:401-409
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Rosenberg, Roger N; Fu, Min; Lambracht-Washington, Doris (2018) Active full-length DNA A?42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology. Alzheimers Res Ther 10:115
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679

Showing the most recent 10 out of 385 publications